Navigation Links
Silence Therapeutics' Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
Date:11/10/2010

LONDON, Nov. 10, 2010 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces positive research findings demonstrating the ability of the Company's lead RNA interference (RNAi) drug candidate, Atu027, to prevent the formation of pulmonary metastasis in various animal models of cancer metastasis.  Researchers showed that Atu027 inhibited multiple key biological processes that enable and contribute to the dissemination and formation of pulmonary metastases in a murine breast cancer metastasis model.  It is important to note that breast cancer cells prefer to metastasize through the bloodstream to the lung.  The findings were published in the latest edition of the scientific journal Clinical Cancer Research in a peer-reviewed paper entitled; "Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models."

Atu027 is a proven inhibitor of the expression of PKN3, a molecule that is believed to play an important role in the progression of cancer and metastasis formation in particular.  In the study, researchers administered Atu027 to multiple mouse models of breast cancer to evaluate the drug's ability to prevent the spread of the cancer to the lungs.  Study data demonstrated that Atu027 has a clear inhibitory effect on the formation of pulmonary metastasis.  With metastasis directly linked to high rates of mortality in cancer patients, the prevention of metastasis dissemination and formation is a critical goal of cancer treatment.

"While the demonstrated inhibition of pulmonary metastasis formation was a positive and important outcome of this study, equally important is what we learned regarding the manner in which Atu027 is able to achieve this effect.  These findings showed that in addition to our previously published research demonstrating its ability to inhibit metastasis through the lymphatic system, Atu027 also appears to interrupt the metastatic processes that involve blood flow to the lung," stated Klaus Giese, Ph.D., chief scientific officer at Silence Therapeutics.  "Importantly, these data provide us with evidence that Atu027, which targets vascular endothelial cells, may be modulating not only the tumor vasculature itself, but the pulmonary vasculature as well."

"We are very pleased to be able to continue to identify the mechanisms that drive Atu027's therapeutic activity while concurrently advancing the product through its ongoing Phase 1 study.  Building this collection of novel data on Atu027 will only serve to inform our ongoing development efforts and allow us to maximize the opportunity for success with this program," said Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.

Atu027, a liposomal AtuRNAi™ formulation in clinical development for systemic cancer indications, is one of the most clinically advanced RNAi therapeutics in the area of oncology.  In June 2009, Silence initiated an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid (malignant) tumors involving single, as well as, repeated intravenous administration.  The study is expected to be completed early in the second half of 2011.

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The company's strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts Medical School on three patent families associated with the "Zamore Design Rules," which cover broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development activities in Berlin and operations in Redwood City, CA.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.


'/>"/>
SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):